At a glance
ClinicalIndex Comparison Record- ✓Adult age >18 years with NSCLC receiving one of nine specified oral therapies
- ✓Possession of a mobile device capable of sending and receiving SMS text messages
- ✓Ability to respond to questions and engage with chatbot in English
- ✓Medical oncologist approval to be approached for study participation
- ✕Inability to engage with SMS text-messaging platform
- ✕Concurrent enrollment in a therapeutic clinical trial
- ✕Taking more than one oral targeted therapy or concurrent chemotherapy during the study window
- ✕Lack of approval from the patient's oncologist
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Implementation Strategies for Monitoring Adherence in Real Time
In Brief
A clinical study evaluating Conversational Agent/Chatbot and Usual Care for Lung Cancer and 2 related conditions. Active but no longer recruiting, targeting 75 participants across 1 site.
Detailed Summary
The objective of this project is to identify effective strategies to help patients with lung cancer manage side effects and achieve optimal adherence to oral targeted therapies. To achieve this objective, we will evaluate the effect of a novel, bidirectional conversational agent, compared to usual care, on adherence to oral targeted therapies using a two-arm randomized controlled trial, and explore how multilevel factors impact the acceptability and effectiveness of this strategy by collecting qualitative and quantitative data from clinicians and patients.
Study Details
Timeline
Interventions
Via text messages, the bidirectional, conversation agent provides specific dosing instructions and motivational reminders to promote oral targeted therapy adherence and symptom management. Patients can report symptoms at any time via text message and are also prompted to report symptoms and medication adherence at periodic intervals. Reported symptoms are monitored and managed algorithmically according severity. High-grade symptoms are triaged directly to the patients' cancer care team. Patients in the intervention arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.
Patients in the control arm will receive usual care, which includes receiving information about dosing and self-administration of oral therapy, and anticipatory guidance for patients regarding management of side effects. Patients in the control arm will use MEMS caps to enable capture of the primary outcome and asked to complete longitudinal surveys.